Expertise in
20
conditions

Eric W. Deutsch

Gustave Roussy
Villejuif, FR 
Expertise in
20
conditions
Gustave Roussy
Villejuif, FR 

Overview

Eric Deutsch practices practicing medicine in Villejuif, France.

Mr. Deutsch is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Delayed Growth, Cervical Cancer, Leukocytosis, Penectomy, and Mastectomy.

He is actively involved in clinical research, co-authoring 516 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Gustave Roussy
Villejuif, 94805, France
Other Locations
401 Terry Ave N, Seattle, WA 98109
1441 N 34th Street, Seattle, WA 98103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or Anus
A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or Anus
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Drug, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab +/- Ipilimumab
Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab +/- Ipilimumab
Enrollment Status: Terminated
Publish Date: February 21, 2023
Intervention Type: Drug, Other
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
Enrollment Status: Completed
Publish Date: October 04, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 1
A Phase 1b Trial of LY2606368 in Combination With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Cancer
A Phase 1b Trial of LY2606368 in Combination With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Cancer
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
View 4 Less Clinical Trials

516 Total Publications

Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.
Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.
Journal: Nature reviews. Gastroenterology & hepatology
Published: August 12, 2026

Frequently Asked Questions about Eric W. Deutsch

Is Eric W. Deutsch a top-rated expert for Delayed Growth?

MediFind is an objective health platform that identifies experts based on real-world data. Eric W. Deutsch is classified as an Elite expert for Delayed Growth, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Eric W. Deutsch participate in research or clinical trials?

Yes. Eric W. Deutsch has published 516 articles and abstracts on conditions like Delayed Growth. You can view a list of Eric W. Deutsch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Deutsch's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 32 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile